GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc 6017 Snell Ave, Ste 357, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, email@example.com
#LF-EK50005 Human BDNF ELISA kit
Product name : Human BDNF ELISA kit
Catalog number : LF-EK50005
Supplier name : Abfron
Data sheet: Ask more or other datasheet now !
About this Product :Human BDNF ELISA kit
Storage and handling
All components of the Human BDNF ELISA kit should be stored at temperatures between 2 and 8 degrees Celsius. In order to keep the sensitivity of the kit, please don not freeze and thaw repeatedly.
More Details about
Human BDNF ELISA
Catalog # LF-EK50005 (1 kit)
Sandwich Enzyme-Linked Immunosorbent Assay for Quantitative Detection of human BDNF
For research use only
Not for diagnostic or therapeutic purposes
Brain-derived neurotrophic factor (BDNF) is a prosurvival factor induced by cortical neurons that is necessary for survival of striatal neurons in the brain. It is a secreted protein with the molecular weight of 27.8kDa, consisting of 247 amino acids. It is known to promote neuronal survival and differentiation. BDNF shares substantial amino acid sequence identity with nerve growth factor (NGF). BDNF and neurotrophin-3 (NT-3) are two recently cloned neurotrophic factors that are homologous to NGF. mRNA products of the BDNF and NT-3 genes are detected in the adult human brain, suggesting that these proteins are involved in the maintenance of the adult nervous system.1 BDNF and other neurotrophins are critically involved in long-term potentiation (LTP). BDNF-mediated LTP is induced postsynaptically.2 BDNF has trophic effects on serotonergic (5-HT) neurons in the central nervous system.3 BDNF has an essential maintenance function in the regulation of anxiety-related behavior and in food intake through central mediators in both the basal and fasted state.4 It plays a role in treating breathing disorders such as respiratory insufficiency after spinal injury.5 The mature form of BDNF is identical in all mammals examined, and the gene encoding human BDNF to chromosome 11, band p13. 6
2. Principles of Method
AbFrontier’s human BDNF ELISA Kit was based on standard sandwich enzyme-linked immune-sorbent assay technology. Human BDNF specific-specific polyclonal antibodies were precoated onto 96-well plates. The human specific detection monoclonal antibodies were biotinylated. The test samples and biotinylated detection antibodies were added to the wells subsequently and then followed by washing with PBS or TBS buffer. Avidin-Biotin-Peroxidase Complex was added and unbound conjugates were washed away with PBS or TBS buffer. HRP substrate TMB was used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the human BDNF amount of sample captured in plate.
3. Intended Use
The AbFrontier human BDNF ELISA kit is to be used for the in vitro quantitative determination of human BDNF in human serum, human plasma, cell lysate and buffered solution. The assay will recognize both native and recombinant human BDNF.
This kit has been configured for research use only and is not to be used in diagnostic procedures.
4. Storage and Stability
All kit components of this kit are stable at 2 to 8℃. Any unused reconstituted standard should be discarded or frozen at -70℃. Standard can be frozen and thawed one time only without loss of immunoreactivity.
5. Chemical Hazard
- Stop solution: This reagent is an irritant to eyes, skin and mucous membranes. Avoid contact with eyes, skin and clothing. Wear suitable protective clothing, gloves and eye protection. In the event of contact with eyes or skin, wash immediately with plenty of water.
- All reagents containing Sodium Azide also contain Thimerosal as a preservative. Thimerosal contains Hg thus should be handled with great care.
6. Kit Contents
① 96 Well Plate
: Human BDNF microtiter plate, one plate of 96 wells.
A plate using break-apart strips coated with a monoclonal antibody specific to human
② Standard Protein
: Recombinant human BDNF.
③ Secondary Antibody
: Biotin labeled anti human BDNF antibody.
: Avidin-Biotin-Peroxidase Complex (ABC)
⑤ Substrate (Stabilized chromogen)
: Tetramethylbenzidine (TMB) solution
⑥ Stop Solution
: 1 N solution of sulfuric acid (H2SO4)
Notice for Application of Kit
1． Before using Kit, spin tubes and bring down all components to bottom of tube.
2． Duplicate well assay was recommended for both standard and sample testing.
3． Don’t let 96-well plate dry, dry plate will inactivate active components on plate.
4． In order to avoid marginal effect of plate incubation due to temperature difference (reaction may be stronger in the marginal wells), it is suggested that the diluted ABC and TMB solution will be pre-warmed in 37℃ for 30 min before using.
7. Materials Required But Not Provided
① Microtiter plate reader in standard size.
② Automated plate washer.
③ Distilled or deionized water
④ Calibrated, adjustable precision pipettes, preferably with disposable plastic tips (A manifold multi-channel pipette is desirable for large assays.)
⑤ Data analysis and graphing software
⑥ Vortex mixer
⑦ Polypropylene tubes for diluting and aliquoting standard
⑧ Absorbent paper towels
⑨ Calibrated beakers and graduated cylinders of various sizes
⑩ Washing buffer (neutral PBS or TBS). Preparation of 0.01M TBS: Add 1.2g Tris, 8.5g Nacl; 450μl of purified acetic acid or 700μl of concentrated hydrochloric acid to 1000ml
H2O and adjust pH to 7.2-7.6. Finally, adjust the total volume to 1L. Preparation of 0.01 M PBS: Add 8.5g sodium chloride, 1.4g Na2HPO4 and 0.2g NaH2PO4 to 1000ml distilled water and adjust pH to 7.2-7.6. Finally, adjust the total volume to 1L.
8. Reagent Preparation
1) Plate washing
Discard the solution in the plate without touching the side walls. Blot the plate onto paper towels or other absorbent material. Soak each well with at least 0.3 ml PBS or TBS buffer for 1~2 minutes. Repeat this process two additional times for a total of THREE washes.
Note: For automated washing, aspirate all wells and wash THREE times with PBS or TBS buffer, overfilling wells with PBS or TBS buffer. Blot the plate onto paper towels or other absorbent material.
2) Sample Preparation and Storage
Store samples to be assayed within 24 hours at 2-8°C. For long-term storage, aliquot and freeze samples at -20°C. Avoid repeated freeze-thaw cycles.
o Cell culture supernate, tissue lysate or body fluids: Remove particulates by centrifugation, analyze immediately or aliquot and store at -20°C
o Serum: Allow the serum to clot in a serum separator tube (about 30 min) at room temperature. Centrifuge at approximately 1000 X g for 15 min. Analyze the serum immediately or aliquot and store frozen at -20°C.
o Plasma: Collect plasma using heparin, EDTA, citrate as an anticoagulant. Centrifuge for 15 min at 2-8℃ at 1500 x g within 30 min of collection. For eliminating the platelet effect, suggesting that further centrifugation for 10 min at 2-8°C at 10000 x g. Analyze immediately or aliquot and store samples at -20°C.
3) Sample Dilution Guideline
The user needs to estimate the concentration of the target protein in the sample and select a proper dilution factor so that the diluted target protein concentration falls near the middle of the linear regime in the standard curve. Dilute the sample using the provided diluent buffer. The following is a guideline for sample dilution. Several trials may be
necessary in practice. The sample must be well mixed with the diluents buffer.
o High target protein concentration (20-200ng/ml). The working dilution is 1:100. i.e. Add 1 μl sample into 99 μl sample diluent buffer.
o Medium target protein concentration (2-20ng/ml). The working dilution is 1:10. i.e. Add 10 μl sample into 90 μl sample diluent buffer.
o Low target protein concentration (31.2-2,000pg/ml). The working dilution is 1:2. i.e. Add 50 μl sample to 50 μl sample diluent buffer.
o Very Low target protein concentration (≤31.2pg/ml). No dilution necessary, or the working dilution is 1:2.
4) Reagent Preparation and Storage
A. Reconstitution of the human BDNF standard：BDNF standard solution should be prepared no more than 2 hours prior to the experiment. Two tubes of human BDNF standard (10ng per tube) are included in each kit. Use one tube for each experiment.
a. 10,000pg/ml of human BDNF standard solution: Add 1 ml sample diluent buffer into one tube, keep the tube at room temperature for 10 min and mix thoroughly.
b. 2000pg/ml of human BDNF standard solution: Add 0.2 ml of the above 10ng/ml BDNF standard solution into 0.8 ml sample diluent buffer and mix thoroughly.
c. 1000pg/ml→31.2pg/ml of human BDNF standard solutions: Label 6 Eppendorf tubes with 1000pg/ml, 500pg/ml, 250pg/ml, 125pg/ml, 62.5pg/ml, 31.2pg/ml, respectively. Aliquot 0.3 ml of the sample diluent buffer into each tube. Add 0.3 ml of the above 2000pg/ml human BDNF standard solution into 1st tube and mix. Transfer 0.3 ml from 1st tube to 2nd tube and mix. Transfer 0.3 ml from 2nd tube to 3rd tube and mix, and so on.
Note: The standard solutions are best used within 2 hours. The 10 ng/ml standard solution may be stored at 4°C for up to 12 hours, or at -20°C for up to 48 hours.
Avoid repeated freeze-thaw cycles.
B. Preparation of biotinylated anti-human BDNF antibody working solution: The solution should be prepared no more than 2 hours prior to the experiment.
a. The total volume should be: 0.1ml/well x (the number of wells). (Allowing 0.1-0.2 ml more than total volume)
b. Biotinylated anti-human BDNF antibody should be diluted in 1:99 with the antibody diluent buffer and mixed thoroughly.
C. Preparation of Avidin-Biotin-Peroxidase Complex (ABC) working solution: The solution should be prepared no more than 1 hour prior to the experiment.
a. The total volume should be: 0.1ml/well x (the number of wells). (Allowing 0.1-0.2 ml more than total volume)
b. Avidin- Biotin-Peroxidase Complex (ABC) should be diluted in 1:99 with the ABC dilution buffer and mixed thoroughly.
9. Assay Procedure
The ABC working solution and TMB color developing agent must be kept warm at 37°C for 30 min before use. When diluting samples and reagents, they must be mixed completely and evenly. Standard BDNF detection curve should be prepared for each experiment. The user will decide sample dilution fold by crude estimation of BDNF amount in samples.
1. Aliquot 0.1ml per well of the 2000pg/ml, 1000pg/ml, 500pg/ml, 250pg/ml, 125pg/ml, 62.5pg/ml, 31.2pg/ml human BDNF standard solutions into the precoated 96-well plate. Add 0.1ml of the sample diluent buffer into the control well (Zero well). Add 0.1ml of each properly diluted sample of human sera, plasma, body fluids, tissue lysates or cell culture supernatants to each empty well. See “Sample Dilution Guideline” above for details. We recommend that each human BDNF standard solution and each sample is measured in duplicate.
2. Seal the plate with the cover and incubate at 37°C for 90 min.
3. Remove the cover, discard plate content, and blot the plate onto paper towels or other absorbent material. Do NOT let the wells completely dry at any time.
4. Add 0.1ml of biotinylated anti-human BDNF antibody working solution into each well and incubate the plate at 37°C for 60 min.
5. Wash the plate three times with 0.01M TBS or 0.01M PBS, and each time let washing buffer stay in the wells for 1 min. Discard the washing buffer and blot the plate onto paper towels or other absorbent material.
6. Add 0.1ml of prepared ABC working solution into each well and incubate the plate at
37°C for 30 min.
7. Wash plate 5 times with 0.01M TBS or 0.01M PBS, and each time let washing buffer stay in the wells for 1-2 min. Discard the washing buffer and blot the plate onto paper towels or other absorbent material.
8. Add 90 μl of prepared TMB color developing agent into each well and incubate plate at 37°C for 15-20 min (shades of blue can be seen in the wells with the four most concentrated human BDNF standard solutions; the other wells show no obvious color).
9. Add 0.1ml of prepared TMB stop solution into each well. The color changes into yellow immediately.
10. Read the O.D. absorbance at 450nm in a microplate reader within 30 min after adding
the stop solution. For calculation, (the relative O.D.450) = (the O.D.450 of each well) – (the O.D.450 of Zero well). The standard curve can be plotted as the relative O.D.450 of each standard solution (Y) vs. the respective concentration of the standard solution (X). The human BDNF concentration of the samples can be interpolated from the standard curve.
Note: if the samples measured were diluted, multiply the dilution factor to the concentrations from interpolation to obtain the concentration before dilution.
1. Add samples and standards and incubate the plate at 37°C for 90 min. Do not wash.
2. Add biotinylated antibodies and incubate the plate at 37°C for 60 min. Wash plate 3 times with 0.01M TBS.
3. Add ABC working solution and incubate the plate at 37°C for 30 min. Wash plate 5 times with 0.01M TBS.
4. Add TMB color developing agent and incubate the plate at 37°C for 10-15 min.
5. Add TMB stop solution and read.
1) Typical result
Typical Data Obtained from Human BDNF (TMB reaction incubate at 37℃ for 16 min)
Typical Human BDNF ELISA kit Standard Curve
This standard curve was generated at AbFrontier for demonstration purpose only. A standard curve must be run with each assay.
2) Sensitivity: < 2pg/ml
3) Specificity: No detectable cross-reactivity with any other cytokine.
1) Jones, K. R.; Reichardt, L. F. Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc. Nat. Acad. Sci. 87: 8060-8064, 1990.
2) Kovalchuk, Y.; Hanse, E.; Kafitz, K. W.; Konnerth, A. Postsynaptic induction of BDNFmediated long-term potentiation. Science 295: 1729-1734, 2002.
Gentaur Molecular Products
1910 Kampenhout, Belgium
3) Lyons, W. E.; Mamounas, L. A.; Ricaurte, G. A; Coppola, V.; Reid, S. W.; Bora, S. H.; Wihler, C.; Koliatsos, V. E.; Tessarollo, L. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc. Nat. Acad. Sci. 96: 15239-15244, 1999.
4) Rios, M.; Fan, G.; Fekete, C.; Kelly, J.; Bates, B.; Kuehn, R.; Lechan, R. M.; Jaenisch, R.
Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Molec. Endocr. 15: 1748-1757, 2001.
5) Baker-Herman, T. L.; Fuller, D. D.; Bavis, R. W.; Zabka, A. G.; Golder, F. J.; Doperalski, N. J.; Johnson, R. A.; Watters, J. J.; Mitchell, G. S. BDNF is necessary and sufficient for spinal respiratory plasticity following intermittent hypoxia. Nature Neurosci. 7: 48-55, 2004.
6) Maisonpierre, P. C.; Le Beau, M. M.; Espinosa, R., III; Ip, N. Y.; Belluscio, L.; de la Monte, S. M.; Squinto, S.; Furth, M. E.; Yancopoulos, G. D. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions and chromosomal localizations. Genomics 10: 558-568, 1991.
Contact us about this product :
Our team will respond you as soon as possible !
52062 Aachen Deutschland
Support Karolina Elandt
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
firstname.lastname@example.org | Gentaur
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Finland Helsset +358942419041
Magyarország Budapest +3619980547
US New York+17185132983
WP1114: MAPK signaling pathway
WP1337: MAPK signaling pathway
WP2107: pathways in human cancer
WP2137: Prenatal Stress & BDNF
WP2145: serotonin and anxiety
WP2148: Brain derived neurotrophic factor
WP2256: Integrated Pancreatic Cancer Pathway
WP2377: Integrated Pancreatic Cancer Pathway
WP2380: BDNF signaling pathway
WP2431: Spinal Cord Injury
WP2432: Spinal Cord Injury
WP2433: Spinal Cord Injury
WP358: MAPK signaling pathway
WP382: MAPK signaling pathway
WP493: MAPK signaling pathway
WP706: SIDS Susceptibility Pathways
WP769: MAPK signaling pathway
WP880: MAPK signaling pathway
WP998: MAPK signaling pathway
Related Genes :
[TP53 P53] Cellular tumor antigen p53 (Antigen NY-CO-13) (Phosphoprotein p53) (Tumor suppressor p53)
[ELANE ELA2] Neutrophil elastase (EC 22.214.171.124) (Bone marrow serine protease) (Elastase-2) (Human leukocyte elastase) (HLE) (Medullasin) (PMN elastase)
[AR DHTR NR3C4] Androgen receptor (Dihydrotestosterone receptor) (Nuclear receptor subfamily 3 group C member 4)
[RACK1 GNB2L1 HLC7 PIG21] Receptor of activated protein C kinase 1 (Cell proliferation-inducing gene 21 protein) (Guanine nucleotide-binding protein subunit beta-2-like 1) (Guanine nucleotide-binding protein subunit beta-like protein 12.3) (Human lung cancer oncogene 7 protein) (HLC-7) (Receptor for activated C kinase) [Cleaved into: Receptor of activated protein C kinase 1, N-terminally processed (Guanine nucleotide-binding protein subunit beta-2-like 1, N-terminally processed)]
[SCN5A] Sodium channel protein type 5 subunit alpha (HH1) (Sodium channel protein cardiac muscle subunit alpha) (Sodium channel protein type V subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.5)
[EGFR ERBB ERBB1 HER1] Epidermal growth factor receptor (EC 126.96.36.199) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-protein kinase erbB-1)
[CTNNB1 CTNNB OK/SW-cl.35 PRO2286] Catenin beta-1 (Beta-catenin)
[FBN1 FBN] Fibrillin-1 [Cleaved into: Asprosin]
[F8 F8C] Coagulation factor VIII (Antihemophilic factor) (AHF) (Procoagulant component) [Cleaved into: Factor VIIIa heavy chain, 200 kDa isoform; Factor VIIIa heavy chain, 92 kDa isoform; Factor VIII B chain; Factor VIIIa light chain]
[BRCA1 RNF53] Breast cancer type 1 susceptibility protein (EC 6.3.2.-) (RING finger protein 53)
[HBB] Hemoglobin subunit beta (Beta-globin) (Hemoglobin beta chain) [Cleaved into: LVV-hemorphin-7; Spinorphin]
[CCNDBP1 DIP1 GCIP HHM] Cyclin-D1-binding protein 1 (Grap2 and cyclin-D-interacting protein) (Human homolog of Maid)
[gag-pol] Gag-Pol polyprotein (Pr160Gag-Pol) [Cleaved into: Matrix protein p17 (MA); Capsid protein p24 (CA); Spacer peptide 1 (SP1) (p2); Nucleocapsid protein p7 (NC); Transframe peptide (TF); p6-pol (p6*); Protease (EC 188.8.131.52) (PR) (Retropepsin); Reverse transcriptase/ribonuclease H (EC 184.108.40.206) (EC 220.127.116.11) (EC 18.104.22.168) (Exoribonuclease H) (EC 22.214.171.124) (p66 RT); p51 RT; p15; Integrase (IN) (EC 2.7.7.-) (EC 3.1.-.-)]
[SIRT1 SIR2L1] NAD-dependent protein deacetylase sirtuin-1 (hSIRT1) (EC 3.5.1.-) (Regulatory protein SIR2 homolog 1) (SIR2-like protein 1) (hSIR2) [Cleaved into: SirtT1 75 kDa fragment (75SirT1)]
[AKAP13 BRX HT31 LBC] A-kinase anchor protein 13 (AKAP-13) (AKAP-Lbc) (Breast cancer nuclear receptor-binding auxiliary protein) (Guanine nucleotide exchange factor Lbc) (Human thyroid-anchoring protein 31) (Lymphoid blast crisis oncogene) (LBC oncogene) (Non-oncogenic Rho GTPase-specific GTP exchange factor) (Protein kinase A-anchoring protein 13) (PRKA13) (p47)
[APP A4 AD1] Amyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein) (Amyloid precursor protein) (Beta-amyloid precursor protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-amyloid protein 42 (Beta-APP42); Beta-amyloid protein 40 (Beta-APP40); C83; P3(42); P3(40); C80; Gamma-secretase C-terminal fragment 59 (Amyloid intracellular domain 59) (AICD-59) (AID(59)) (Gamma-CTF(59)); Gamma-secretase C-terminal fragment 57 (Amyloid intracellular domain 57) (AICD-57) (AID(57)) (Gamma-CTF(57)); Gamma-secretase C-terminal fragment 50 (Amyloid intracellular domain 50) (AICD-50) (AID(50)) (Gamma-CTF(50)); C31]
[LRRK2 PARK8] Leucine-rich repeat serine/threonine-protein kinase 2 (EC 126.96.36.199) (Dardarin)
[UBE3A E6AP EPVE6AP HPVE6A] Ubiquitin-protein ligase E3A (EC 6.3.2.-) (E6AP ubiquitin-protein ligase) (Human papillomavirus E6-associated protein) (Oncogenic protein-associated protein E6-AP) (Renal carcinoma antigen NY-REN-54)
[GOLGA2] Golgin subfamily A member 2 (130 kDa cis-Golgi matrix protein) (GM130) (GM130 autoantigen) (Golgin-95)
[AKT1 PKB RAC] RAC-alpha serine/threonine-protein kinase (EC 188.8.131.52) (Protein kinase B) (PKB) (Protein kinase B alpha) (PKB alpha) (Proto-oncogene c-Akt) (RAC-PK-alpha)
[INSR] Insulin receptor (IR) (EC 184.108.40.206) (CD antigen CD220) [Cleaved into: Insulin receptor subunit alpha; Insulin receptor subunit beta]
[TGFB1 TGFB] Transforming growth factor beta-1 (TGF-beta-1) [Cleaved into: Latency-associated peptide (LAP)]
[SCN1A NAC1 SCN1] Sodium channel protein type 1 subunit alpha (Sodium channel protein brain I subunit alpha) (Sodium channel protein type I subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.1)
[TTN] Titin (EC 220.127.116.11) (Connectin) (Rhabdomyosarcoma antigen MU-RMS-40.14)
[SRC SRC1] Proto-oncogene tyrosine-protein kinase Src (EC 18.104.22.168) (Proto-oncogene c-Src) (pp60c-src) (p60-Src)
[KIT SCFR] Mast/stem cell growth factor receptor Kit (SCFR) (EC 22.214.171.124) (Piebald trait protein) (PBT) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (p145 c-kit) (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (CD antigen CD117)
[FGFR2 BEK KGFR KSAM] Fibroblast growth factor receptor 2 (FGFR-2) (EC 126.96.36.199) (K-sam) (KGFR) (Keratinocyte growth factor receptor) (CD antigen CD332)
[EPHA3 ETK ETK1 HEK TYRO4] Ephrin type-A receptor 3 (EC 188.8.131.52) (EPH-like kinase 4) (EK4) (hEK4) (HEK) (Human embryo kinase) (Tyrosine-protein kinase TYRO4) (Tyrosine-protein kinase receptor ETK1) (Eph-like tyrosine kinase 1)
[KCNQ1 KCNA8 KCNA9 KVLQT1] Potassium voltage-gated channel subfamily KQT member 1 (IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1) (KQT-like 1) (Voltage-gated potassium channel subunit Kv7.1)
[APOE] Apolipoprotein E (Apo-E)
 Epigenome-Wide Meta-Analysis of Methylation in Children Related to Prenatal NO2 Air Pollution Exposure.
 An Effective Occipitomental View Enhancement Based on Adaptive Morphological Texture Analysis.
 Using pot-magnets to enable stable and scalable electromagnetic tactile displays.
 Experimental Validation of Dynamic Granger Causality for Inferring Stimulus-evoked Sub-100ms Timing Differences from fMRI.
 Dynamic Projection Mapping onto Deforming Non-rigid Surface using Deformable Dot Cluster Marker.
 Web Image Search Re-ranking with Click-based Similarity and Typicality.
 Radiometric Compensation of Images Projected on Non-White Surfaces by Exploiting Chromatic Adaptation and Perceptual Anchoring.
 Sparse SVD Method for High Resolution Extraction of the Dispersion Curves of Ultrasonic Guided Waves.
 Electrical Stimulation of the Human Cerebral Cortex by Extracranial Muscle Activity:Effect Quantification with Intracranial EEG and FEM Simulations.
 Effect of a single dose of retigabine in cortical excitability parameters: A cross-over, double-blind placebo-controlled TMS study.
Enter catalog number :